Literature DB >> 7561920

Hereditary myokymia and paroxysmal ataxia linked to chromosome 12 is responsive to acetazolamide.

W J Lubbers1, E R Brunt, H Scheffer, M Litt, R Stulp, D L Browne, T W van Weerden.   

Abstract

A sixth family with autosomal dominantly inherited myokymia and paroxysmal ataxia is described. The syndrome in this family is linked to the recently discovered locus for inherited myokymia and paroxysmal ataxia on the human chromosome 12p, and a missense mutation is shown in the KCNA1 gene. The attacks of ataxia in this family compare well with those of previously described families and similarly are precipitated by kinesigenic stimuli, exertion, and startle. Responsiveness of these attacks to low dose acetazolamide is confirmed, but some loss of efficacy occurs with prolonged treatment, and side effects are notable. Although not all affected family members showed myokymia on clinical examination, electromyography invariably showed myokymic discharges, in one patient only after a short provocation with regional ischaemia. One affected family member also had attacks of paroxysmal kinesigenic choreoathetosis, responsive to carbamazepine.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7561920      PMCID: PMC486077          DOI: 10.1136/jnnp.59.4.400

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  15 in total

1.  Paroxysmal choreoathetosis after head injury.

Authors:  M E Drake; R D Jackson; C A Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-07       Impact factor: 10.154

2.  Hereditary paroxysmal ataxia: response to acetazolamide.

Authors:  R C Griggs; R T Moxley; R A Lafrance; J McQuillen
Journal:  Neurology       Date:  1978-12       Impact factor: 9.910

3.  [Familial episodic ataxia (author's transl)].

Authors:  P Wolf
Journal:  Nervenarzt       Date:  1980-06       Impact factor: 1.214

4.  Hereditary myokymia and periodic ataxia.

Authors:  D H VanDyke; R C Griggs; M J Murphy; M N Goldstein
Journal:  J Neurol Sci       Date:  1975-05       Impact factor: 3.181

5.  Paroxysmal dystonic choreoathetosis in a patient with familial ataxia.

Authors:  R Mayeux; S Fahn
Journal:  Neurology       Date:  1982-10       Impact factor: 9.910

6.  Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1.

Authors:  D L Browne; S T Gancher; J G Nutt; E R Brunt; E A Smith; P Kramer; M Litt
Journal:  Nat Genet       Date:  1994-10       Impact factor: 38.330

7.  Autosomal dominant episodic ataxia: a heterogeneous syndrome.

Authors:  S T Gancher; J G Nutt
Journal:  Mov Disord       Date:  1986       Impact factor: 10.338

8.  Paroxysmal choreoathetosis following head injury.

Authors:  J J Robin
Journal:  Ann Neurol       Date:  1977-11       Impact factor: 10.422

9.  A recessively inherited ataxia with episodes of dystonia.

Authors:  N R Graff-Radford
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-05       Impact factor: 10.154

10.  Kinesigenic choreoathetosis due to brain injury.

Authors:  J C Richardson; J L Howes; M J Celinski; R G Allman
Journal:  Can J Neurol Sci       Date:  1987-11       Impact factor: 2.104

View more
  13 in total

Review 1.  The complex clinical and genetic classification of inherited ataxias. I. Dominant ataxias.

Authors:  S Di Donato
Journal:  Ital J Neurol Sci       Date:  1998-12

2.  Cerebellar Ataxia.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

Review 3.  The Clinical Spectrum of Autosomal-Dominant Episodic Ataxias.

Authors:  Stefan Kipfer; Michael Strupp
Journal:  Mov Disord Clin Pract       Date:  2014-07-28

4.  Use of acetazolamide in sulfonamide-allergic patients with neurologic channelopathies.

Authors:  Daniel Platt; Robert C Griggs
Journal:  Arch Neurol       Date:  2011-12-12

5.  Variable K(+) channel subunit dysfunction in inherited mutations of KCNA1.

Authors:  Ruth Rea; Alexander Spauschus; Louise H Eunson; Michael G Hanna; Dimitri M Kullmann
Journal:  J Physiol       Date:  2002-01-01       Impact factor: 5.182

6.  De novo loss- or gain-of-function mutations in KCNA2 cause epileptic encephalopathy.

Authors:  Steffen Syrbe; Ulrike B S Hedrich; Erik Riesch; Tania Djémié; Stephan Müller; Rikke S Møller; Bridget Maher; Laura Hernandez-Hernandez; Matthis Synofzik; Hande S Caglayan; Mutluay Arslan; José M Serratosa; Michael Nothnagel; Patrick May; Roland Krause; Heidrun Löffler; Katja Detert; Thomas Dorn; Heinrich Vogt; Günter Krämer; Ludger Schöls; Primus E Mullis; Tarja Linnankivi; Anna-Elina Lehesjoki; Katalin Sterbova; Dana C Craiu; Dorota Hoffman-Zacharska; Christian M Korff; Yvonne G Weber; Maja Steinlin; Sabina Gallati; Astrid Bertsche; Matthias K Bernhard; Andreas Merkenschlager; Wieland Kiess; Michael Gonzalez; Stephan Züchner; Aarno Palotie; Arvid Suls; Peter De Jonghe; Ingo Helbig; Saskia Biskup; Markus Wolff; Snezana Maljevic; Rebecca Schüle; Sanjay M Sisodiya; Sarah Weckhuysen; Holger Lerche; Johannes R Lemke
Journal:  Nat Genet       Date:  2015-03-09       Impact factor: 38.330

Review 7.  Clinical Spectrum of KCNA1 Mutations: New Insights into Episodic Ataxia and Epilepsy Comorbidity.

Authors:  Kelsey Paulhus; Lauren Ammerman; Edward Glasscock
Journal:  Int J Mol Sci       Date:  2020-04-17       Impact factor: 5.923

Review 8.  New insights into the pathogenesis and therapeutics of episodic ataxia type 1.

Authors:  Maria Cristina D'Adamo; Sonia Hasan; Luca Guglielmi; Ilenio Servettini; Marta Cenciarini; Luigi Catacuzzeno; Fabio Franciolini
Journal:  Front Cell Neurosci       Date:  2015-08-19       Impact factor: 5.505

9.  Downward vertical gaze palsy as a prominent manifestation of episodic ataxia type 2: a case report.

Authors:  Reza Shervin Badv; Ali Niksirat
Journal:  Iran J Child Neurol       Date:  2013

Review 10.  Episodic ataxia type 1: a neuronal potassium channelopathy.

Authors:  Sanjeev Rajakulendran; Stephanie Schorge; Dimitri M Kullmann; Michael G Hanna
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.